Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Irx Therapeutics, which discovers and develops proprietary drugs for the treatment of cancer and viral diseases, has appointed Scott Freeman as its new COO.
Subscribe to our email newsletter
Dr Freeman has been a senior medical advisor to Irx since 2007. Prior to joining Irx, Dr Freeman served as vice president of clinical development at Onyx Pharmaceutical from 2001 to 2006.
Dr Freeman earned his BA from the University of Colorado and received his MD from the University of Nevada in 1983.
John Hadden II, president and CEO of Irx Therapeutics, said: “Dr Freeman has been a valued part of our team for over a year and has earned our trust and respect. We look forward to his contribution in his expanded role as we move into the global Phase III clinical trial of our lead product candidate, Irx-2.”